MA47500B1 - Dérivés de pyrrolo[1,2-b]pyridazine - Google Patents
Dérivés de pyrrolo[1,2-b]pyridazineInfo
- Publication number
- MA47500B1 MA47500B1 MA47500A MA47500A MA47500B1 MA 47500 B1 MA47500 B1 MA 47500B1 MA 47500 A MA47500 A MA 47500A MA 47500 A MA47500 A MA 47500A MA 47500 B1 MA47500 B1 MA 47500B1
- Authority
- MA
- Morocco
- Prior art keywords
- pyrrolo
- pyridazine derivatives
- pyridazine
- derivatives
- variables
- Prior art date
Links
- NISJKLIMPQPAQS-UHFFFAOYSA-N pyrrolo[1,2-b]pyridazine Chemical class C1=CC=NN2C=CC=C21 NISJKLIMPQPAQS-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
L'invention concerne un composé de formule (i), dans laquelle les groupes de variables sont définis dans la description.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762460013P | 2017-02-16 | 2017-02-16 | |
PCT/US2018/018431 WO2018152368A1 (fr) | 2017-02-16 | 2018-02-15 | Dérivés de pyrrolo [1,2-b] pyridazine |
Publications (2)
Publication Number | Publication Date |
---|---|
MA47500A MA47500A (fr) | 2019-12-25 |
MA47500B1 true MA47500B1 (fr) | 2024-02-29 |
Family
ID=61563476
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA47500A MA47500B1 (fr) | 2017-02-16 | 2018-02-15 | Dérivés de pyrrolo[1,2-b]pyridazine |
Country Status (32)
Country | Link |
---|---|
US (1) | US10336762B2 (fr) |
EP (1) | EP3583105B1 (fr) |
JP (3) | JP6924267B2 (fr) |
KR (1) | KR102337055B1 (fr) |
CN (1) | CN110300754A (fr) |
AR (1) | AR110935A1 (fr) |
AU (2) | AU2018221812B2 (fr) |
BR (1) | BR102018002879A2 (fr) |
CA (1) | CA3050148A1 (fr) |
CL (1) | CL2019002306A1 (fr) |
CO (1) | CO2019008868A2 (fr) |
CR (1) | CR20190373A (fr) |
DK (1) | DK3583105T3 (fr) |
DO (1) | DOP2019000214A (fr) |
EA (1) | EA201991544A1 (fr) |
FI (1) | FI3583105T3 (fr) |
IL (1) | IL267979B (fr) |
JO (1) | JOP20180011A1 (fr) |
LT (1) | LT3583105T (fr) |
MA (1) | MA47500B1 (fr) |
MX (1) | MX2019009840A (fr) |
PE (1) | PE20191540A1 (fr) |
PH (1) | PH12019550128A1 (fr) |
PT (1) | PT3583105T (fr) |
RS (1) | RS65397B1 (fr) |
SA (1) | SA519402462B1 (fr) |
SG (1) | SG11201906763RA (fr) |
TW (3) | TW202340194A (fr) |
UA (1) | UA124548C2 (fr) |
UY (1) | UY37608A (fr) |
WO (1) | WO2018152368A1 (fr) |
ZA (1) | ZA201905456B (fr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018338314A1 (en) | 2017-09-22 | 2020-04-09 | Kymera Therapeutics, Inc | Protein degraders and uses thereof |
EP3684366A4 (fr) | 2017-09-22 | 2021-09-08 | Kymera Therapeutics, Inc. | Ligands crbn et utilisations de ces derniers |
WO2019111218A1 (fr) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs d'irak4 |
US10874743B2 (en) | 2017-12-26 | 2020-12-29 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
EP3737666A4 (fr) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | Agents de dégradation de protéines et utilisations associées |
EP3737675A4 (fr) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | Ligands crbn et leurs utilisations |
US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
TW202136268A (zh) * | 2018-07-13 | 2021-10-01 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
AU2019321267B2 (en) * | 2018-08-13 | 2022-07-14 | Gilead Sciences, Inc. | Pyrrolo[1,2-b]pyridazine derivatives as IRAK4 inhibitors |
CA3105795C (fr) * | 2018-08-13 | 2024-01-16 | Gilead Sciences, Inc. | Derives de pyrrolo [1,2-b] pyridazine en tant qu'inhibiteurs d'irak4 |
BR112021010484A2 (pt) | 2018-11-30 | 2021-08-24 | Kymera Therapeutics, Inc. | Degradadores de irak e usos dos mesmos |
JP2022526901A (ja) | 2019-03-19 | 2022-05-27 | ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド | 駆虫性アザベンゾチオフェンおよびアザベンゾフラン化合物 |
CN111821308B (zh) * | 2019-04-15 | 2021-10-08 | 中国科学院上海药物研究所 | 雷藤舒在制备用于治疗非酒精性脂肪性肝病的药物中的应用 |
CN110755451B (zh) * | 2019-11-23 | 2021-07-06 | 博雅干细胞科技有限公司 | 用于治疗骨关节炎的间充质干细胞组合物及其用途 |
CN110755452B (zh) * | 2019-11-23 | 2021-07-06 | 博雅干细胞科技有限公司 | 干细胞治疗骨关节炎的用途 |
BR112022011651A2 (pt) | 2019-12-17 | 2022-08-23 | Kymera Therapeutics Inc | Degradadores de irak e usos dos mesmos |
EP4076524A4 (fr) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | Agents de dégradation d'irak et leurs utilisations |
PE20231205A1 (es) | 2020-05-29 | 2023-08-17 | Boehringer Ingelheim Animal Health Usa Inc | Compuestos heterociclicos como anthelminticos |
TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
US11976071B2 (en) | 2021-08-18 | 2024-05-07 | Gilead Sciences, Inc. | Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases |
WO2023247552A1 (fr) | 2022-06-21 | 2023-12-28 | Syngenta Crop Protection Ag | Dérivés de carboxamide hétérocycliques bicycliques microbiocides |
WO2024089191A1 (fr) | 2022-10-27 | 2024-05-02 | Syngenta Crop Protection Ag | Dérivés de dihydrooxadiazine hétérobicycliques microbiocides |
CN117849327A (zh) * | 2024-03-06 | 2024-04-09 | 军科正源(北京)药物研究有限责任公司 | 用于检测苏金单抗抗药性抗体的方法 |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003030902A1 (fr) | 2001-10-09 | 2003-04-17 | Tularik Inc. | Derives d'imidazole comme agents anti-inflammatoires |
WO2008016643A2 (fr) | 2006-08-01 | 2008-02-07 | Cytokinetics, Incorporated | Entités chimiques, compositions et méthodes |
CA2663100A1 (fr) | 2006-09-07 | 2008-03-13 | Biogen Idec Ma Inc. | Derives d'indazole utilises comme modulateurs de la kinase associee au recepteur de l'interleukine-1 |
DE102009033208A1 (de) | 2009-07-15 | 2011-01-20 | Merck Patent Gmbh | Aminopyridinderivate |
JP2012254939A (ja) | 2009-10-07 | 2012-12-27 | Astellas Pharma Inc | オキサゾール化合物 |
MX340490B (es) | 2010-07-13 | 2016-07-11 | F Hoffmann-La Roche Ag * | Derivados de pirazolo [1, 5a] pirimidina y de tieno [3, 2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4). |
RS57375B1 (sr) | 2010-11-19 | 2018-08-31 | Ligand Pharm Inc | Heterociklični amini i njihove upotrebe |
RS55165B1 (sr) | 2010-12-20 | 2017-01-31 | Merck Serono Sa | Indazolil triazol derivati kao irak inhibitori |
EP2663312B1 (fr) | 2011-01-10 | 2017-10-11 | Nimbus Iris, Inc. | Inhibiteurs d'irak et leurs utilisation |
US9169260B2 (en) | 2011-03-22 | 2015-10-27 | Merck Sharp & Dohme Corp. | Amidopyrazole inhibitors of interleukin receptor-associated kinases |
WO2013042137A1 (fr) | 2011-09-19 | 2013-03-28 | Aurigene Discovery Technologies Limited | Hétérocycles bicycliques convenant comme inhibiteurs de l'irak4 |
EP2773207B1 (fr) | 2011-10-31 | 2018-03-07 | Merck Sharp & Dohme Corp. | Aminopyrimidinones en tant qu'inhibiteurs de kinases associées au récepteur de l'interleukine |
CA2849566C (fr) | 2011-11-09 | 2021-02-09 | Cancer Research Technology Limited | Composes de type 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile et leur utilisation therapeutique |
AU2013207972B2 (en) | 2012-01-10 | 2017-06-15 | Nimbus Iris, Inc. | IRAK inhibitors and uses thereof |
WO2013106614A1 (fr) | 2012-01-13 | 2013-07-18 | Bristol-Myers Squibb Company | Composés pyridyles à substitution triazolyle utiles comme inhibiteurs de kinases |
CN104254533B (zh) | 2012-01-13 | 2017-09-08 | 百时美施贵宝公司 | 用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物 |
US9242975B2 (en) | 2012-01-13 | 2016-01-26 | Bristol-Myers Squibb Company | Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors |
US9216991B2 (en) | 2012-07-10 | 2015-12-22 | Ares Trading S.A. | Pyrimidine pyrazolyl derivatives |
US20140018361A1 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
CA2878040A1 (fr) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Inhibiteurs d'irak et leurs utilisations |
US9085586B2 (en) | 2012-07-11 | 2015-07-21 | Nimbus Iris, Inc. | IRAK inhibitors and uses thereof |
US9586948B2 (en) | 2012-10-08 | 2017-03-07 | Merck Sharp & Dohme Corp. | Inhibitors of IRAK4 activity |
WO2014058685A1 (fr) | 2012-10-08 | 2014-04-17 | Merck Sharp & Dohme Corp. | Inhibiteurs de l'activité de l'irak4 |
TW201422606A (zh) | 2012-11-08 | 2014-06-16 | 必治妥美雅史谷比公司 | 可作爲激酶調節劑之經雙環雜環取代之吡啶化合物 |
EP2917186B1 (fr) | 2012-11-08 | 2017-10-18 | Bristol-Myers Squibb Company | Composés de pyrimidine substitués par alkylamide utiles dans la modulation d'il-12, il-23 et/ou ifn |
BR112015009850A2 (pt) | 2012-11-08 | 2017-07-11 | Bristol Myers Squibb Co | compostos de piridila substituídos por heteroarila úteis como moduladores de quinase |
ES2702148T3 (es) | 2012-11-08 | 2019-02-27 | Bristol Myers Squibb Co | Compuestos heterocíclicos sustituidos con amida útiles como moduladores de il-12, il-23 y/o ifn-alfa |
CN104955824B (zh) | 2012-11-20 | 2017-09-22 | 豪夫迈·罗氏有限公司 | 作为含t790m的egfr突变体的抑制剂的氨基嘧啶化合物 |
US9175007B2 (en) | 2013-01-10 | 2015-11-03 | Nimbus Iris, Inc. | IRAK inhibitors and uses thereof |
CA2900442C (fr) | 2013-02-07 | 2021-09-21 | Merck Patent Gmbh | Derives de pyridazinone macrocycliques |
JP6483624B2 (ja) | 2013-02-07 | 2019-03-13 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | ピリダジノン−アミド誘導体 |
US9617282B2 (en) | 2013-03-15 | 2017-04-11 | Biogen Ma Inc. | Macrocyclic compounds as IRAK4 inhibitors for the treatment of inflammatory diseases |
WO2014210354A1 (fr) | 2013-06-28 | 2014-12-31 | Genentech, Inc. | Composés d'azaindazole en tant qu'inhibiteurs de la t790m contenant des mutants de l'egfr |
US20160166576A1 (en) | 2013-07-11 | 2016-06-16 | Merck Sharp & Dohme Corp. | Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4) |
RU2016110852A (ru) | 2013-09-27 | 2017-10-30 | Нимбус Айрис, Инк. | Ингибиторы irak и их применения |
BR112016010041B1 (pt) | 2013-11-08 | 2023-04-18 | Takeda Pharmaceutical Company Limited | Composto heterocíclico com uma ação inibitória de irak-4, composição farmacêutica, e, uso do composto |
TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
UY35935A (es) * | 2014-01-03 | 2015-06-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4 |
US10314841B2 (en) | 2014-01-09 | 2019-06-11 | Merck Patent Gmbh | Substituted pyrazoles as IRAK inhibitors |
US10160753B2 (en) | 2014-01-10 | 2018-12-25 | Aurigene Discovery Technologies Limited | Indazole compounds as IRAK4 inhibitors |
PT3466955T (pt) | 2014-01-13 | 2021-01-29 | Aurigene Discovery Tech Ltd | Método de preparação de derivados de oxazolo[4,5-b] piridina e tiazolo[4,5-b] piridina como inibidores de irak-4 para o tratamento do cancro |
LT3536685T (lt) | 2014-04-04 | 2022-04-25 | Pfizer Inc. | Biciklinio sulieto heteroarilo arba arilo junginiai ir jų naudojimas kaip irak4 inhibitorių |
CN106413715A (zh) | 2014-04-22 | 2017-02-15 | 林伯士艾瑞斯公司 | Irak抑制剂和其用途 |
EA201692418A1 (ru) | 2014-06-20 | 2017-04-28 | Ауриджен Дискавери Текнолоджиз Лимитед | Замещенные индазольные соединения в качестве irak4 ингибиторов |
AR101229A1 (es) | 2014-07-18 | 2016-11-30 | Biogen Ma Inc | Agentes inhibidores de irak4 |
EP3200789B1 (fr) | 2014-09-30 | 2019-11-06 | Merck Sharp & Dohme Corp. | Inhibiteurs de l'activité d'irak4 |
US9969749B2 (en) | 2014-09-30 | 2018-05-15 | Merck Sharp & Dohme Corp. | Inhibitors of IRAK4 activity |
EP3200790B1 (fr) | 2014-09-30 | 2020-08-26 | Merck Sharp & Dohme Corp. | Inhibiteurs de l'activité d'irak4 |
US9926330B2 (en) | 2014-09-30 | 2018-03-27 | Merck Sharp & Dohme Corp. | Inhibitors of IRAK4 activity |
PL3221306T3 (pl) | 2014-11-20 | 2020-09-07 | Merck Patent Gmbh | Związki heteroarylowe jako inhibitory irak i ich zastosowania |
JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
JP6835727B2 (ja) | 2015-02-05 | 2021-02-24 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Irak1/4阻害剤としての大環状化合物及びその使用 |
JP6920202B2 (ja) | 2015-02-06 | 2021-08-18 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Irak阻害剤としてのピリダジノン大環状化合物及びその使用 |
US10040802B2 (en) | 2015-03-12 | 2018-08-07 | Merck Sharp & Dohme Corp. | Thienopyrazine inhibitors of IRAK4 activity |
EP3268367B8 (fr) | 2015-03-12 | 2022-11-16 | Merck Sharp & Dohme LLC | Carboxamides utilisés comme inhibiteurs de l'activité de l'irak4 |
US10329294B2 (en) | 2015-03-12 | 2019-06-25 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine inhibitors of IRAK4 activity |
US10040798B2 (en) | 2015-03-12 | 2018-08-07 | Merck Sharp & Dohme Corp. | Pyrrolopyridazine inhibitors of IRAK4 activity |
WO2016144848A1 (fr) | 2015-03-12 | 2016-09-15 | Merck Sharp & Dohme Corp. | Inhibiteurs de pyrrolotriazine de l'activité d'irak4 |
BR112017022349B1 (pt) | 2015-04-22 | 2023-11-07 | Rigel Pharmaceuticals, Inc | Composto, composição o compreendendo, seus usos, e, método |
TW201701879A (zh) | 2015-04-30 | 2017-01-16 | 拜耳製藥公司 | Irak4抑制劑組合 |
JP6843775B2 (ja) | 2015-06-24 | 2021-03-17 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | ヘテロアリール置換のアミノピリジン化合物 |
EP3313844B1 (fr) | 2015-06-24 | 2020-08-26 | Bristol-Myers Squibb Company | Composés d'aminopyridine à substitution hétéroaryle |
UY36749A (es) * | 2015-06-24 | 2016-12-30 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4, y composiciones farmacéuticas que los contienen |
WO2017004133A1 (fr) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Inhibiteurs d'irak et utilisations de ceux-ci |
WO2017004134A1 (fr) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Inhibiteurs d'irak et leurs utilisations |
EA201890308A1 (ru) | 2015-07-15 | 2018-08-31 | Ориджин Дискавери Текнолоджиз Лимитед | Замещенные азасоединения как ингибиторы irak-4 |
CN108026065A (zh) | 2015-07-15 | 2018-05-11 | 奥列基因发现技术有限公司 | 作为irak-4抑制剂的吲唑及氮杂吲唑化合物 |
DK3331879T3 (da) | 2015-08-04 | 2020-08-10 | Rigel Pharmaceuticals Inc | Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne |
PL3331877T3 (pl) | 2015-08-04 | 2022-01-31 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Pochodna pirazolopirymidyny i jej zastosowania |
CN107531725B (zh) | 2015-08-13 | 2021-03-19 | 北京韩美药品有限公司 | Irak4抑制剂及其应用 |
KR102048719B1 (ko) | 2015-08-13 | 2019-11-26 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | Irak4억제제 및 이의 용도 |
CA2995153A1 (fr) | 2015-08-13 | 2017-02-16 | Pfizer Inc. | Composes aryle ou heteroaryle condenses bicycliques |
PT3341367T (pt) | 2015-08-27 | 2021-04-19 | Pfizer | Compostos de arilo ou heteroarilo bicíclicos fusionados como moduladores de irak4 |
US9969710B2 (en) | 2015-09-18 | 2018-05-15 | Merck Patent Gmbh | Heteroaryl compounds as IRAK inhibitors and uses thereof |
AU2016323612B2 (en) | 2015-09-18 | 2021-04-08 | Merck Patent Gmbh | Heteroaryl compounds as IRAK inhibitors and uses thereof |
GB201518456D0 (en) | 2015-10-19 | 2015-12-02 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases |
WO2017108744A1 (fr) | 2015-12-22 | 2017-06-29 | Bayer Pharma Aktiengesellschaft | Nouveaux indazoles substitués, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour produire des médicaments |
CN108473498B (zh) | 2015-12-22 | 2021-11-02 | 豪夫迈·罗氏有限公司 | 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物 |
EP3405465B1 (fr) | 2016-01-20 | 2021-10-13 | Biogen MA Inc. | Agents inhibiteurs d'irak4 |
MA44759B1 (fr) | 2016-04-29 | 2024-01-31 | Bayer Pharma AG | Forme polymorphe de n-(6-(2-hydroxypropan-2-yl)-2-[2-(méthylsulfonyl)éthyl]-2h-indazol-5-yl)-6-(trifluorométhyl)pyridine-2-carboxamide |
WO2017205769A1 (fr) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibiteurs de la kinase associée au récepteur de l'interleukine 1 |
WO2017205762A1 (fr) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibiteurs de la kinase associée au récepteur de l'interleukine 1 |
WO2017205766A1 (fr) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibiteurs de la kinase associée au récepteur de l'interleukine-1 |
WO2017207385A1 (fr) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | 3-methylindazoles substitués, leur procédé de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la production de médicaments |
US10710983B2 (en) | 2016-06-27 | 2020-07-14 | Rigel Pharmaceuticals, Inc. | 2,4-diamino-pyrimidine compounds and method for making and using the compounds |
CA3040526A1 (fr) | 2016-10-26 | 2018-05-03 | Rigel Pharmaceuticals, Inc. | Composes d'amide de pyrazole comme inhibiteurs d'irak |
WO2018083085A1 (fr) | 2016-11-02 | 2018-05-11 | F. Hoffmann-La Roche Ag | Dérivés pyrazolo [1,5a]pyrimidine en tant que modulateurs d'irak 4 |
-
2017
- 2017-02-16 JO JOP/2018/0011A patent/JOP20180011A1/ar unknown
-
2018
- 2018-02-05 TW TW111148495A patent/TW202340194A/zh unknown
- 2018-02-05 TW TW110124807A patent/TWI790674B/zh active
- 2018-02-05 TW TW107103929A patent/TWI733982B/zh active
- 2018-02-14 BR BR102018002879A patent/BR102018002879A2/pt active Search and Examination
- 2018-02-15 FI FIEP18708796.0T patent/FI3583105T3/fi active
- 2018-02-15 RS RS20240424A patent/RS65397B1/sr unknown
- 2018-02-15 CR CR20190373A patent/CR20190373A/es unknown
- 2018-02-15 UA UAA201908592A patent/UA124548C2/uk unknown
- 2018-02-15 CA CA3050148A patent/CA3050148A1/fr active Pending
- 2018-02-15 US US15/898,095 patent/US10336762B2/en active Active
- 2018-02-15 PE PE2019001681A patent/PE20191540A1/es unknown
- 2018-02-15 LT LTEPPCT/US2018/018431T patent/LT3583105T/lt unknown
- 2018-02-15 CN CN201880012452.8A patent/CN110300754A/zh active Pending
- 2018-02-15 JP JP2019543909A patent/JP6924267B2/ja active Active
- 2018-02-15 IL IL267979A patent/IL267979B/en unknown
- 2018-02-15 EP EP18708796.0A patent/EP3583105B1/fr active Active
- 2018-02-15 KR KR1020197026476A patent/KR102337055B1/ko active IP Right Grant
- 2018-02-15 SG SG11201906763RA patent/SG11201906763RA/en unknown
- 2018-02-15 PT PT187087960T patent/PT3583105T/pt unknown
- 2018-02-15 EA EA201991544A patent/EA201991544A1/ru unknown
- 2018-02-15 AU AU2018221812A patent/AU2018221812B2/en active Active
- 2018-02-15 WO PCT/US2018/018431 patent/WO2018152368A1/fr unknown
- 2018-02-15 MX MX2019009840A patent/MX2019009840A/es unknown
- 2018-02-15 MA MA47500A patent/MA47500B1/fr unknown
- 2018-02-15 DK DK18708796.0T patent/DK3583105T3/da active
- 2018-02-16 AR ARP180100369A patent/AR110935A1/es unknown
- 2018-02-16 UY UY0001037608A patent/UY37608A/es not_active Application Discontinuation
-
2019
- 2019-07-11 PH PH12019550128A patent/PH12019550128A1/en unknown
- 2019-08-14 CL CL2019002306A patent/CL2019002306A1/es unknown
- 2019-08-15 DO DO2019000214A patent/DOP2019000214A/es unknown
- 2019-08-15 CO CONC2019/0008868A patent/CO2019008868A2/es unknown
- 2019-08-18 SA SA519402462A patent/SA519402462B1/ar unknown
- 2019-08-19 ZA ZA2019/05456A patent/ZA201905456B/en unknown
-
2021
- 2021-07-30 JP JP2021125416A patent/JP2021176902A/ja not_active Withdrawn
-
2022
- 2022-09-08 AU AU2022228165A patent/AU2022228165A1/en active Pending
-
2023
- 2023-04-28 JP JP2023074711A patent/JP2023100791A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA47500B1 (fr) | Dérivés de pyrrolo[1,2-b]pyridazine | |
MX2019003254A (es) | Compuestos y metodos para la modulacion de ido y tdo, e indicaciones de estos. | |
PH12019500480A1 (en) | Pyridine compound | |
MA52987A (fr) | Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak | |
MX2020007265A (es) | Derivados de rapamicina. | |
PH12017502171B1 (en) | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | |
EA201791011A1 (ru) | 3-ЗАМЕЩЕННЫЕ 5-АМИНО-6H-ТИАЗОЛО[4,5-d]ПИРИМИДИН-2,7-ДИОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ВИРУСНЫХ ИНФЕКЦИЙ | |
MA37940A2 (fr) | Nouveaux dérivés bicycliques | |
MA40302A1 (fr) | Dérivés de carbazole | |
MX2018013133A (es) | Compuesto de pirazolo[1,5-a]pirimidina. | |
MX2015012111A (es) | Moduladores de ship1 y métodos relacionados con éstos. | |
EA201891769A1 (ru) | СПОСОБ ПОЛУЧЕНИЯ СОЕДИНЕНИЯ ПИРРОЛО[3,2-d]ПИРИМИДИНА И ПРОМЕЖУТОЧНЫХ СОЕДИНЕНИЙ | |
DOP2020000118A (es) | Proceso para la preparación de derivados de quinolina | |
MX2020013297A (es) | Compuestos para el tratamiento o la prevencion de enfermedades hepaticas. | |
JOP20200030A1 (ar) | مركب خماسي الحلقة | |
EA201991355A1 (ru) | Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта | |
PH12019501171A1 (en) | Pyrido [3, 4-d] pyrimidine derivative and pharmaceutically acceptable salt thereof | |
EA202092858A1 (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[1,2-b]ПИРИДАЗИНА | |
PH12018500999A1 (en) | Sodium channel blocker | |
TN2019000038A1 (en) | Triazolopyrazinone derivative useful as a human pde1 inhibitor | |
MA53165A (fr) | Dérivés d'imidazo[1,2-b]pyridazine utilisés en tant qu'inhibiteurs de trk | |
PH12019502046A1 (en) | Pyrrolotriazine derivatives as kinase inhibitor | |
MX2017003415A (es) | Un derivado de tetrahidropirrolo [3,4-d] [1,3]tiazina como inhibidor de bace. | |
NZ748746A (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
CO2017003225A2 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos |